November 27, 2001 — BOCA RATON, FL — Disease Sciences, Inc. has closed on its majority interest in HealthSpan Sciences, Inc., a privately held San Diego California-based drug development company, for four million shares of restricted common stock.

HealthSpan has two patent filings with a class of compounds that may have potential as a treatment for a wide range of degenerative diseases in both humans and animals. HealthSpan’s proposed drug analogs may provide safe small-molecule treatments for various degenerative diseases such as cancer, cardiovascular disease, and macular degeneration. Some of the proposed drug analogs may be anti-microbials or immune-stimulants, which could lead these analogs to have potential applications in treating chronic infections such as AIDS, Hepatitis C, or even TSE diseases.

“This acquisition once again demonstrates our commitment to the execution of our disciplined acquisition growth strategy by adding a broad array of technologies. We believe that Dr. Villeponteau and the HealthSpan team offers tremendous potential,” said Wayne Goldstein, CEO of Diseases Sciences, Inc.

Dr. Goldstein added, “Challenging economic conditions continues to create opportunities for Disease Sciences to grow through selective acquisitions in biotech.”